Early prediction of phenotypic severity in Citrullinemia Type 1

Matthias Zielonka, Stefan Kölker, Florian Gleich, Nicolas Stützenberger, Sandesh C S Nagamani, Andrea L Gropman, Georg F Hoffmann, Sven F Garbade, Roland Posset, Urea Cycle Disorders Consortium (UCDC) and the European Registry and Network for Intoxication type Metabolic Diseases (E-IMD) Consortia Study Group, Adrijan Sarajlija, Anastasia Skouma, Andreas Schulze, Angeles Garcia-Cazorla, A M Lund, Anil Jalan, Andrew Morris, Carlo Dionisi-Vici, Corinne De Laet, Elisa Leão Teles, G A Diaz, G T Berry, Irma Payan-Walters, Javier Blasco-Alonso, Jennifer Seminara, Jirair K Bedoyan, J Lawrence Merritt 2nd, Lindsay C Burrage, Marc Yudkoff, Manuel Schiff, Matthias R Baumgartner, Nicholas Ah Mew, Nastassja Himmelreich, Peter Freisinger, Peter M van Hasselt, Roshni Vara, Susan A Berry, Suzanne Hollander, Matthias Zielonka, Stefan Kölker, Florian Gleich, Nicolas Stützenberger, Sandesh C S Nagamani, Andrea L Gropman, Georg F Hoffmann, Sven F Garbade, Roland Posset, Urea Cycle Disorders Consortium (UCDC) and the European Registry and Network for Intoxication type Metabolic Diseases (E-IMD) Consortia Study Group, Adrijan Sarajlija, Anastasia Skouma, Andreas Schulze, Angeles Garcia-Cazorla, A M Lund, Anil Jalan, Andrew Morris, Carlo Dionisi-Vici, Corinne De Laet, Elisa Leão Teles, G A Diaz, G T Berry, Irma Payan-Walters, Javier Blasco-Alonso, Jennifer Seminara, Jirair K Bedoyan, J Lawrence Merritt 2nd, Lindsay C Burrage, Marc Yudkoff, Manuel Schiff, Matthias R Baumgartner, Nicholas Ah Mew, Nastassja Himmelreich, Peter Freisinger, Peter M van Hasselt, Roshni Vara, Susan A Berry, Suzanne Hollander

Abstract

Objective: Citrullinemia type 1 (CTLN1) is an inherited metabolic disease affecting the brain which is detectable by newborn screening. The clinical spectrum is highly variable including individuals with lethal hyperammonemic encephalopathy in the newborn period and individuals with a mild-to-moderate or asymptomatic disease course. Since the phenotypic severity has not been predictable early during the disease course so far, we aimed to design a reliable disease prediction model.

Methods: We used a newly established mammalian biallelic expression system to determine residual enzymatic activity of argininosuccinate synthetase 1 (ASS1; OMIM #215700) in 71 individuals with CTLN1, representing 48 ASS1 gene variants and 50 different, mostly compound heterozygous combinations in total. Residual enzymatic ASS1 activity was correlated to standardized biochemical and clinical endpoints available from the UCDC and E-IMD databases.

Results: Residual enzymatic ASS1 activity correlates with peak plasma ammonium and L-citrulline concentrations at initial presentation. Individuals with 8% of residual enzymatic ASS1 activity or less had more frequent and more severe hyperammonemic events and lower cognitive function than those above 8%, highlighting that residual enzymatic ASS1 activity allows reliable severity prediction. Noteworthy, empiric clinical practice of affected individuals is in line with the predicted disease severity supporting the notion of a risk stratification-based guidance of therapeutic decision-making based on residual enzymatic ASS1 activity in the future.

Interpretation: Residual enzymatic ASS1 activity reliably predicts the phenotypic severity in CTLN1. We propose a new severity-adjusted classification system for individuals with CTLN1 based on the activity results of the newly established biallelic expression system.

Conflict of interest statement

SK receives funding from Horizon Pharma Ireland Limited for the European Post‐Authorization Registry for Ravicti® (glycerol phenylbutyrate) oral liquid in partnership with the E‐IMD (RRPE) (EU PAS Register no. EUPAS17267; http://www.encepp.eu/). The sponsors have in no way influenced the design, conductance, analysis and report of the present study. All other authors declare that they have no conflict of interest.

© 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.

Figures

Figure 1
Figure 1
Residual enzymatic ASS1 activity correlates with initial biochemical parameters. (A) NH4 + max (µmol/L) subject to residual enzymatic ASS1 activity (%) as determined in the biallelic expression system. Each point represents a single patient (n = 52). Gray line displays estimated regression curve. GAM‐analysis, P < 0.001, R2 = 0.29. (B) Boxplot illustrating NH4 + max (µmol/L) with a residual enzymatic ASS1 activity below or equal to 8.1% (n = 32) and above 8.1% (n = 20). Data are shown as median (black thick line) and mean (triangle), length of the box corresponds to interquartile range (IQR), upper and lower whiskers correspond to max. 1.5 × IQR, each point represents an outlier. Recursive partitioning, P < 0.001. (C) Peak plasma L‐citrulline concentration subject to residual enzymatic ASS1 activity (%). Each point represents a single patient (n = 33). Gray line displays estimated regression curve. GAM‐analysis, P < 0.001, R2 = 0.46. ASS1, argininosuccinate synthetase 1.
Figure 2
Figure 2
Residual enzymatic ASS1 activity predicts number and severity of HAEs. (A) Number of HAEs (NH4 + max ≥ 100 µmol/L) per year subject to residual enzymatic ASS1 activity (%). Each point represents a single patient (n = 43). Gray line displays estimated regression curve. GAM‐analysis, P = 0.002, R2 = 0.26. (B) Boxplot illustrating number of HAEs (NH4 + max ≥ 100 µmol/L) per year with a residual enzymatic ASS1 activity below or equal to 8.1% (n = 17) or above 8.1% (n = 26). Data are shown as median (black thick line) and mean (triangle), length of the box corresponds to IQR, upper and lower whiskers correspond to max. 1.5 × IQR, each point represents an outlier. Recursive partitioning, P = 0.003. (C) NH4 + max during most severe HAE subject to residual enzymatic ASS1 activity (%). Each point represents a single patient (n = 26). Gray line displays estimated regression curve. GAM‐analysis, P = 0.007, R2 = 0.23. (D) Boxplot illustrating NH4 + max during most severe HAE with a residual enzymatic ASS1 activity below or equal to 8.1% (n = 17) or above 8.1% (n = 9). Data are shown as median (black thick line) and mean (triangle), length of the box corresponds to IQR, upper and lower whiskers correspond to max. 1.5 × IQR, each point represents an outlier. Recursive partitioning, P = 0.01. ASS1, argininosuccinate synthetase 1.
Figure 3
Figure 3
Residual enzymatic ASS1 activity correlates with cognitive outcome. (A) Cognitive SDS subject to residual enzymatic ASS1 activity (%). Each point represents a single patient (n = 34). Grey line indicates linear regression curve. Linear regression, P = 0.029, R2 = 0.14. (B) Boxplot illustrating cognitive SDS with a residual enzymatic ASS1 activity below or equal to 8.1% (n = 13) and above 8.1% (n = 21). Data are shown as median (black thick line) and mean (triangle), length of the box corresponds to IQR, upper and lower whiskers correspond to max. 1.5 × IQR. Recursive partitioning, P = 0.031. (C) Levelplot for cognitive SDS, residual enzymatic ASS1 activity and age at testing (years). Cognitive SDS values are indicated by color coding in grading from blue to red with descending cognitive SDS. ASS1, argininosuccinate synthetase 1.
Figure 4
Figure 4
Residual enzymatic ASS1 activity predicts organ‐specific manifestations. (A) Boxplot illustrating presence of movement disorders (%) for individuals with a residual enzymatic ASS1 activity below or equal to 19.3% (n = 34) and above 19.3% (n = 26). Gray shading corresponds to individuals with movement disorders in each group. Recursive partitioning, P = 0.03. (B) Boxplot displaying presence of hepatocellular injury (%) for individuals with a residual enzymatic ASS1 activity below or equal to 3.9% (n = 7) and above 3.9% (n = 48). Gray shading corresponds to individuals with episode(s) of hepatocellular injury in each group. Recursive partitioning, P = 0.039. ASS1, argininosuccinate synthetase 1.
Figure 5
Figure 5
Decision for liver transplantation and special education reflects risk‐stratification by residual enzymatic ASS1 activity. (A) Boxplot illustrating proportion of individuals (%) with a liver graft for those with a residual enzymatic ASS1 activity below or equal to 4.8% (n = 13) and above 4.8% (n = 58). Grey shading corresponds to individuals with liver graft in each group. Recursive partitioning, P = 0.011. (B) Boxplot displaying proportion of individuals (%) with special education for those with a residual enzymatic ASS1 activity below or equal to 26.6% (n = 26) and above 26.6% (n = 12). Gray shading corresponds to individuals with special education in each group. Recursive partitioning, P < 0.001. ASS1, argininosuccinate synthetase 1.

References

    1. Summar ML, Koelker S, Freedenberg D, et al. The incidence of urea cycle disorders. Mol Genet Metab 2013;110:179–180.
    1. Posset R, Garbade SF, Boy N, et al. Transatlantic combined and comparative data analysis of 1095 patients with urea cycle disorders‐a successful strategy for clinical research of rare diseases. J Inherit Metab Dis 2019;42:93–106.
    1. Kolker S, Garcia‐Cazorla A, Valayannopoulos V, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentation. J Inherit Metab Dis 2015;38:1041–1057.
    1. Kolker S, Valayannopoulos V, Burlina AB, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype. J Inherit Metab Dis 2015;38:1059–1074.
    1. Burgard P, Kolker S, Haege G, et al. Neonatal mortality and outcome at the end of the first year of life in early onset urea cycle disorders–review and meta‐analysis of observational studies published over more than 35 years. J Inherit Metab Dis 2016;39:219–229.
    1. Posset R, Gropman AL, Nagamani SCS, et al. Impact of diagnosis and therapy on cognitive function in urea cycle disorders. Ann Neurol 2019;86:116–128.
    1. Posset R, Garcia‐Cazorla A, Valayannopoulos V, et al. Age at disease onset and peak ammonium level rather than interventional variables predict the neurological outcome in urea cycle disorders. J Inherit Metab Dis 2016;39:661–672.
    1. Waisbren SE, Cuthbertson D, Burgard P, et al. Biochemical markers and neuropsychological functioning in distal urea cycle disorders. J Inherit Metab Dis 2018;41:657–667.
    1. Kolker S, Dobbelaere D, Haberle J, et al. Networking Across Borders for Individuals with Organic Acidurias and Urea Cycle Disorders: The E‐IMD Consortium. JIMD Rep 2015;22:29–38.
    1. Seminara J, Tuchman M, Krivitzky L, et al. Establishing a consortium for the study of rare diseases: The Urea Cycle Disorders Consortium. Mol Genet Metab 2010;100(Suppl 1):S97–S105.
    1. Diez‐Fernandez C, Rufenacht V, Haberle J. Mutations in the human Argininosuccinate Synthetase (ASS1) Gene, impact on patients, common changes, and structural considerations. Hum Mutat 2017;38:471–484.
    1. Zielonka M, Garbade SF, Kolker S, et al. Quantitative clinical characteristics of 53 patients with MPS VII: a cross‐sectional analysis. Genet Med 2017;19:983–988.
    1. Zielonka M, Garbade SF, Kolker S, et al. A cross‐sectional quantitative analysis of the natural history of Farber disease: an ultra‐orphan condition with rheumatologic and neurological cardinal disease features. Genet Med 2018;20:524–530.
    1. Knottnerus SJG, Nijmeijer SCM, IJlst L, et al. Prediction of phenotypic severity in mucopolysaccharidosis type IIIA. Ann Neurol 2017;82:686–696.
    1. Buerger C, Garbade SF, Dietrich Alber F, et al. Impairment of cognitive function in ornithine transcarbamylase deficiency is global rather than domain‐specific and is associated with disease onset, sex, maximum ammonium, and number of hyperammonemic events. J Inherit Metab Dis 2019;42:243–253.
    1. Pottel H, Hoste L, Dubourg L, et al. An estimated glomerular filtration rate equation for the full age spectrum. Nephrol Dial Transplant 2016;31:798–806.
    1. Gallagher RC, Lam C, Wong D, et al. Significant hepatic involvement in patients with ornithine transcarbamylase deficiency. J Pediatr 2014;164: 720–725.e6.
    1. Wood SN. Fast stable restricted maximum likelihood and marginal likelihood estimation of semiparametric generalized linear models. J R Stat Soc B 2011;73:3–36.
    1. Hothorn T, Hornik K, Zeileis A. Unbiased recursive partitioning: a conditional inference framework. J Comput Graph Stat 2006;15:651–674.
    1. Lagler FB, Gersting SW, Zsifkovits C, et al. New insights into tetrahydrobiopterin pharmacodynamics from Pah enu1/2, a mouse model for compound heterozygous tetrahydrobiopterin‐responsive phenylalanine hydroxylase deficiency. Biochem Pharmacol 2010;80:1563–1571.
    1. Galy B, Ferring‐Appel D, Sauer SW, et al. Iron regulatory proteins secure mitochondrial iron sufficiency and function. Cell Metab 2010;12:194–201.
    1. Kaminski MM, Sauer SW, Kaminski M, et al. T cell activation is driven by an ADP‐dependent glucokinase linking enhanced glycolysis with mitochondrial reactive oxygen species generation. Cell Rep 2012;2:1300–1315.
    1. Sauer SW, Okun JG, Schwab MA, et al. Bioenergetics in glutaryl‐coenzyme A dehydrogenase deficiency: a role for glutaryl‐coenzyme A. J Biol Chem 2005;280:21830–21836.
    1. Nettesheim S, Kolker S, Karall D, et al. Incidence, disease onset and short‐term outcome in urea cycle disorders ‐cross‐border surveillance in Germany, Austria and Switzerland. Orphanet J Rare Dis 2017;12:111.
    1. Enns GM, Berry SA, Berry GT, et al. Survival after treatment with phenylacetate and benzoate for urea‐cycle disorders. N Engl J Med 2007;356:2282–2292.
    1. Castello A, Fischer B, Eichelbaum K, et al. Insights into RNA biology from an atlas of mammalian mRNA‐binding proteins. Cell 2012;149:1393–1406.
    1. Diez‐Fernandez C, Wellauer O, Gemperle C, et al. Kinetic mutations in argininosuccinate synthetase deficiency: characterisation and in vitro correction by substrate supplementation. J Med Genet 2016;53:710–719.
    1. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 2004;1:189–195.
    1. US Food and Drug Administration . Center for drug evaluation and research. Qualification process for drug development tools: guidance for industry and staff, 2014.
    1. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431–440.
    1. Germain DP, Nicholls K, Giugliani R, et al. Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat‐amenable variants: data from the phase 3 randomized, multicenter, double‐blind clinical trial and extension study. Genet Med 2019. 10.1038/s41436-019-0451-z [Epub ahead of print]
    1. Chiriboga CA, Swoboda KJ, Darras BT, et al. Results from a phase 1 study of nusinersen (ISIS‐SMN(Rx)) in children with spinal muscular atrophy. Neurology 2016;86:890–897.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel